{"id":799082,"date":"2025-01-08T16:15:02","date_gmt":"2025-01-08T21:15:02","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/dyne-therapeutics-to-host-investor-conference-call-and-webcast-to-review-new-clinical-data-from-the-achieve-trial-friday-january-10-at-800-a-m-et\/"},"modified":"2025-01-08T16:15:02","modified_gmt":"2025-01-08T21:15:02","slug":"dyne-therapeutics-to-host-investor-conference-call-and-webcast-to-review-new-clinical-data-from-the-achieve-trial-friday-january-10-at-800-a-m-et","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/dyne-therapeutics-to-host-investor-conference-call-and-webcast-to-review-new-clinical-data-from-the-achieve-trial-friday-january-10-at-800-a-m-et\/","title":{"rendered":"Dyne Therapeutics to Host Investor Conference Call and Webcast to Review New Clinical Data from the ACHIEVE Trial Friday, January 10 at 8:00 a.m. ET"},"content":{"rendered":"
\n

WALTHAM, Mass., Jan. 08, 2025 (GLOBE NEWSWIRE) — Dyne Therapeutics, Inc<\/u><\/a>. (Nasdaq: DYN), a clinical-stage neuromuscular disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced it plans to report new clinical data from the Phase 1\/2 ACHIEVE clinical trial on January 10, 2025, and to host a webcast at 8:00 a.m. ET. The company intends to issue a press release prior to the start of the event.<\/p>\n

\n Investor Conference Call and Webcast<\/strong>\n <\/p>\n

The live webcast will be available on the Events & Presentations page of the Investors & Media section of Dyne\u2019s website, and a replay will be accessible for 90 days following the presentation. An accompanying slide presentation will also be available. To view the live webcast and replay, please visit https:\/\/investors.dyne-tx.com\/news-and-events\/events-and-presentations<\/a>.<\/p>\n

\n About Dyne Therapeutics<\/strong>\n <\/p>\n

Dyne Therapeutics is focused on discovering and advancing innovative life-transforming therapeutics for people living with genetically driven neuromuscular diseases. Leveraging the modularity of its FORCE\u2122 platform, Dyne is developing targeted therapeutics that are designed to overcome limitations in delivery to muscle tissue and the central nervous system (CNS). Dyne has a broad pipeline for neuromuscular diseases, including clinical programs for myotonic dystrophy type 1 (DM1) and Duchenne muscular dystrophy (DMD) and a preclinical program for facioscapulohumeral muscular dystrophy (FSHD). For more information, please visit https:\/\/www.dyne-tx.com\/<\/u><\/a>, and follow us on X<\/u><\/a>, LinkedIn<\/u><\/a> and Facebook<\/u><\/a>.<\/p>\n

\n Contacts:<\/strong>\n <\/p>\n

\n Investors<\/strong>
\n
Mike Hencke
Kendall Investor Relations
ir@dyne-tx.com<\/a><\/p>\n

\n Media<\/strong>
\n
Stacy Nartker
Dyne Therapeutics
snartker@dyne-tx.com<\/u><\/a>
781-317-1938<\/p>\n

\"\"
\n
\n \"\"\n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

WALTHAM, Mass., Jan. 08, 2025 (GLOBE NEWSWIRE) — Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage neuromuscular disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced it plans to report new clinical data from the Phase 1\/2 ACHIEVE clinical trial on January 10, 2025, and to host a webcast at 8:00 a.m. ET. The company intends to issue a press release prior to the start of the event. Investor Conference Call and Webcast The live webcast will be available on the Events & Presentations page of the Investors & Media section of Dyne\u2019s website, and a replay will be accessible for 90 days following the presentation. An accompanying slide presentation will also be … <\/p>\n

Continue reading “Dyne Therapeutics to Host Investor Conference Call and Webcast to Review New Clinical Data from the ACHIEVE Trial Friday, January 10 at 8:00 a.m. ET”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-799082","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nDyne Therapeutics to Host Investor Conference Call and Webcast to Review New Clinical Data from the ACHIEVE Trial Friday, January 10 at 8:00 a.m. ET - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/dyne-therapeutics-to-host-investor-conference-call-and-webcast-to-review-new-clinical-data-from-the-achieve-trial-friday-january-10-at-800-a-m-et\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Dyne Therapeutics to Host Investor Conference Call and Webcast to Review New Clinical Data from the ACHIEVE Trial Friday, January 10 at 8:00 a.m. ET - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"WALTHAM, Mass., Jan. 08, 2025 (GLOBE NEWSWIRE) — Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage neuromuscular disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced it plans to report new clinical data from the Phase 1\/2 ACHIEVE clinical trial on January 10, 2025, and to host a webcast at 8:00 a.m. ET. The company intends to issue a press release prior to the start of the event. Investor Conference Call and Webcast The live webcast will be available on the Events & Presentations page of the Investors & Media section of Dyne\u2019s website, and a replay will be accessible for 90 days following the presentation. An accompanying slide presentation will also be … Continue reading "Dyne Therapeutics to Host Investor Conference Call and Webcast to Review New Clinical Data from the ACHIEVE Trial Friday, January 10 at 8:00 a.m. ET"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/dyne-therapeutics-to-host-investor-conference-call-and-webcast-to-review-new-clinical-data-from-the-achieve-trial-friday-january-10-at-800-a-m-et\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-01-08T21:15:02+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMyODkxMSM2NjgzMzQxIzIyMDA4OTI=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dyne-therapeutics-to-host-investor-conference-call-and-webcast-to-review-new-clinical-data-from-the-achieve-trial-friday-january-10-at-800-a-m-et\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dyne-therapeutics-to-host-investor-conference-call-and-webcast-to-review-new-clinical-data-from-the-achieve-trial-friday-january-10-at-800-a-m-et\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Dyne Therapeutics to Host Investor Conference Call and Webcast to Review New Clinical Data from the ACHIEVE Trial Friday, January 10 at 8:00 a.m. ET\",\"datePublished\":\"2025-01-08T21:15:02+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dyne-therapeutics-to-host-investor-conference-call-and-webcast-to-review-new-clinical-data-from-the-achieve-trial-friday-january-10-at-800-a-m-et\\\/\"},\"wordCount\":271,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dyne-therapeutics-to-host-investor-conference-call-and-webcast-to-review-new-clinical-data-from-the-achieve-trial-friday-january-10-at-800-a-m-et\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTMyODkxMSM2NjgzMzQxIzIyMDA4OTI=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dyne-therapeutics-to-host-investor-conference-call-and-webcast-to-review-new-clinical-data-from-the-achieve-trial-friday-january-10-at-800-a-m-et\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dyne-therapeutics-to-host-investor-conference-call-and-webcast-to-review-new-clinical-data-from-the-achieve-trial-friday-january-10-at-800-a-m-et\\\/\",\"name\":\"Dyne Therapeutics to Host Investor Conference Call and Webcast to Review New Clinical Data from the ACHIEVE Trial Friday, January 10 at 8:00 a.m. ET - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dyne-therapeutics-to-host-investor-conference-call-and-webcast-to-review-new-clinical-data-from-the-achieve-trial-friday-january-10-at-800-a-m-et\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dyne-therapeutics-to-host-investor-conference-call-and-webcast-to-review-new-clinical-data-from-the-achieve-trial-friday-january-10-at-800-a-m-et\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTMyODkxMSM2NjgzMzQxIzIyMDA4OTI=\",\"datePublished\":\"2025-01-08T21:15:02+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dyne-therapeutics-to-host-investor-conference-call-and-webcast-to-review-new-clinical-data-from-the-achieve-trial-friday-january-10-at-800-a-m-et\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dyne-therapeutics-to-host-investor-conference-call-and-webcast-to-review-new-clinical-data-from-the-achieve-trial-friday-january-10-at-800-a-m-et\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dyne-therapeutics-to-host-investor-conference-call-and-webcast-to-review-new-clinical-data-from-the-achieve-trial-friday-january-10-at-800-a-m-et\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTMyODkxMSM2NjgzMzQxIzIyMDA4OTI=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTMyODkxMSM2NjgzMzQxIzIyMDA4OTI=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dyne-therapeutics-to-host-investor-conference-call-and-webcast-to-review-new-clinical-data-from-the-achieve-trial-friday-january-10-at-800-a-m-et\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Dyne Therapeutics to Host Investor Conference Call and Webcast to Review New Clinical Data from the ACHIEVE Trial Friday, January 10 at 8:00 a.m. ET\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Dyne Therapeutics to Host Investor Conference Call and Webcast to Review New Clinical Data from the ACHIEVE Trial Friday, January 10 at 8:00 a.m. ET - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/dyne-therapeutics-to-host-investor-conference-call-and-webcast-to-review-new-clinical-data-from-the-achieve-trial-friday-january-10-at-800-a-m-et\/","og_locale":"en_US","og_type":"article","og_title":"Dyne Therapeutics to Host Investor Conference Call and Webcast to Review New Clinical Data from the ACHIEVE Trial Friday, January 10 at 8:00 a.m. ET - Market Newsdesk","og_description":"WALTHAM, Mass., Jan. 08, 2025 (GLOBE NEWSWIRE) — Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage neuromuscular disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced it plans to report new clinical data from the Phase 1\/2 ACHIEVE clinical trial on January 10, 2025, and to host a webcast at 8:00 a.m. ET. The company intends to issue a press release prior to the start of the event. Investor Conference Call and Webcast The live webcast will be available on the Events & Presentations page of the Investors & Media section of Dyne\u2019s website, and a replay will be accessible for 90 days following the presentation. An accompanying slide presentation will also be … Continue reading \"Dyne Therapeutics to Host Investor Conference Call and Webcast to Review New Clinical Data from the ACHIEVE Trial Friday, January 10 at 8:00 a.m. ET\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/dyne-therapeutics-to-host-investor-conference-call-and-webcast-to-review-new-clinical-data-from-the-achieve-trial-friday-january-10-at-800-a-m-et\/","og_site_name":"Market Newsdesk","article_published_time":"2025-01-08T21:15:02+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMyODkxMSM2NjgzMzQxIzIyMDA4OTI=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dyne-therapeutics-to-host-investor-conference-call-and-webcast-to-review-new-clinical-data-from-the-achieve-trial-friday-january-10-at-800-a-m-et\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dyne-therapeutics-to-host-investor-conference-call-and-webcast-to-review-new-clinical-data-from-the-achieve-trial-friday-january-10-at-800-a-m-et\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Dyne Therapeutics to Host Investor Conference Call and Webcast to Review New Clinical Data from the ACHIEVE Trial Friday, January 10 at 8:00 a.m. ET","datePublished":"2025-01-08T21:15:02+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dyne-therapeutics-to-host-investor-conference-call-and-webcast-to-review-new-clinical-data-from-the-achieve-trial-friday-january-10-at-800-a-m-et\/"},"wordCount":271,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dyne-therapeutics-to-host-investor-conference-call-and-webcast-to-review-new-clinical-data-from-the-achieve-trial-friday-january-10-at-800-a-m-et\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMyODkxMSM2NjgzMzQxIzIyMDA4OTI=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dyne-therapeutics-to-host-investor-conference-call-and-webcast-to-review-new-clinical-data-from-the-achieve-trial-friday-january-10-at-800-a-m-et\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/dyne-therapeutics-to-host-investor-conference-call-and-webcast-to-review-new-clinical-data-from-the-achieve-trial-friday-january-10-at-800-a-m-et\/","name":"Dyne Therapeutics to Host Investor Conference Call and Webcast to Review New Clinical Data from the ACHIEVE Trial Friday, January 10 at 8:00 a.m. ET - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dyne-therapeutics-to-host-investor-conference-call-and-webcast-to-review-new-clinical-data-from-the-achieve-trial-friday-january-10-at-800-a-m-et\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dyne-therapeutics-to-host-investor-conference-call-and-webcast-to-review-new-clinical-data-from-the-achieve-trial-friday-january-10-at-800-a-m-et\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMyODkxMSM2NjgzMzQxIzIyMDA4OTI=","datePublished":"2025-01-08T21:15:02+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dyne-therapeutics-to-host-investor-conference-call-and-webcast-to-review-new-clinical-data-from-the-achieve-trial-friday-january-10-at-800-a-m-et\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/dyne-therapeutics-to-host-investor-conference-call-and-webcast-to-review-new-clinical-data-from-the-achieve-trial-friday-january-10-at-800-a-m-et\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dyne-therapeutics-to-host-investor-conference-call-and-webcast-to-review-new-clinical-data-from-the-achieve-trial-friday-january-10-at-800-a-m-et\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMyODkxMSM2NjgzMzQxIzIyMDA4OTI=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMyODkxMSM2NjgzMzQxIzIyMDA4OTI="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dyne-therapeutics-to-host-investor-conference-call-and-webcast-to-review-new-clinical-data-from-the-achieve-trial-friday-january-10-at-800-a-m-et\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Dyne Therapeutics to Host Investor Conference Call and Webcast to Review New Clinical Data from the ACHIEVE Trial Friday, January 10 at 8:00 a.m. ET"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/799082","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=799082"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/799082\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=799082"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=799082"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=799082"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}